Printer Friendly

Complete radiologic response in metastatic castration-resistant prostate cancer treated with cabazitaxel.

Dear editor,

About 20-40% of patients who undergo primary therapy for early-stage prostate cancer, experience biochemical relapse of which 30-70% develop metastatic disease within 10 years (1) and the majority will become resistant to castration (CRPC). Since 2004, docetaxel has been the first-line cytotoxic treatment in treating metastatic CRPC. However, many mCRPC patients eventually become resistant to docetaxel, for whom available treatment options are limited. (2) Cabazitaxel, a next-generation taxane, is the first agent to demonstrate improved survival post-docetaxel in mCRPC patients. (3-5)

In 2007, a 62-year-old patient presented to our clinic with a PSA=6.5 ng/ml. He refused a biopsy, and returned in August 2009 with PSA=19 ng/ml. Prostate biopsy was done in September 2009, followed by radical prostatectomy. The pathology report came back as prostate adenocarcinoma with Gleason 3+4, extensive PNI, and involvement of both lobes as well as the right seminal vesicle (pT3). Iliac lymph nodes were free of tumor. After the surgery, PSA reduced to 0.1 ng/ml and he was planned to receive radiation therapy to the prostate bed followed by monthly decapeptyl. In November 2011, while still on androgen deprivation therapy with PSA=0.05 ng/ml, he developed dyspnea and hemoptysis. A chest CT scan revealed several masses in both lungs and metastasis was proved by biopsy (figure 1).

Chemotherapy with docetaxel and prednisolone was started. After the 6th cycle, CT scan showed a significant reduction in size and number of lesions, and chemotherapy continued for two more cycles.

Six weeks after the 8th cycle of chemotherapy, he complained of dyspnea again, and at that time, the chest CT scan revealed an increase in the size and number of pulmonary lesions (figure 2).

Therefore, chemotherapy with cabazitaxel 25 mg/[m.sup.2] every three weeks with prednisolone 10 mg daily was started. After the third cycle of cabazitaxel, chest CT scan showed a complete recovery (figure 3).

Chemotherapy continued for three more cycles (with G-CSF support) and the treatment was completed in August 2013. The patient tolerated the chemotherapy with minor side effects, and eight months after the completion of the treatment, he was still symptom free.

Conflict of Interest: None declared.

Bahram Mofid [1], MD; Samira Azghandi [1], MD; Ahmad Rezazadeh Mafi [2], MD, MSc

[1] Clinical Oncologist, Shohada Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran;

[2] Clinical Oncologist, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence:

Ahmad Rezazadeh Mafi, MD; Department of Clinical Oncology, Imam Hossein Hospital,

Nezamabad, Tehran, Iran

Tel: +98 912 779 6354

Fax: +98 21 22231034

Email: ahmadrmafi@yahoo.com

Received: 20 July 2014

Revised: 14 October 2014

Accepted: 2 November 2014

References

(1) Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61:212-36. doi: 10.3322/caac.20121. PubMed PMID: 21685461.

(2) Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. Journal of hematology & oncology. 2011; 4:18. doi: 10.1186/17568722-4-18. PubMed PMID: 21513551; PubMed Central PMCID: PMC3102641.

(3) de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-54. doi: 10.1016/s0140-6736(10)61389-x. PubMed PMID: 20888992.

(4) Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer Treat Rev. 2014; 40:170-7. doi: 10.1016/j.ctrv.2013.06.008. PubMed PMID: 23958310.

(5) Nightingale G, Ryu J. Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P. T. 2012; 37:440-8. PubMed PMID: 23091336; PubMed Central PMCID: PMC3474423.
COPYRIGHT 2015 Shiraz University of Medical Sciences
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Photo Clinic
Author:Mofid, Bahram; Azghandi, Samira; Mafi, Ahmad Rezazadeh
Publication:Iranian Journal of Medical Sciences
Article Type:Letter to the editor
Date:May 1, 2015
Words:641
Previous Article:Prevalence of neonatal hyperphenylalaninemia in Yazd Province, Iran.
Next Article:Comparing different epinephrine concentrations for spinal anesthesia in cesarean section: a double-blind randomized clinical trial.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters